首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >125I-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature.
【2h】

125I-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature.

机译:125I -PD151242:位于人肾中的内皮素ETA受体的选择性配体其定位于肾脉管系统。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

1. The linear tetrapeptide radioligand, [125I]-PD151242 was used to characterize ETA receptors in human kidney which is an ETB-rich tissue. Saturation binding assays with [125I]-PD151242 revealed a single population of high affinity endothelin receptors: KD = 0.75 +/- 0.07 nM and Bmax = 48.4 +/- 1.6 fmol mg-1 protein (n = 3 individuals +/- s.e.mean). Hill slopes were close to unity and a one site fit was preferred to a two site model. 2. ETA-receptor-selective ligands competed for [125I]-PD151242 binding with sub-nanomolar affinity: BQ123 KD = 0.43 +/- 0.10 nM, Bmax = 46.6 +/- 7.9 fmol mg-1 protein; FR139317, KD = 0.37 +/- 0.06 nM, Bmax = 39.5 +/- 6.5 fmol mg-1 protein (n = 3 individuals +/- s.e.mean). In each case, monophasic inhibition curves were obtained and a one site fit was preferred to a two site model. The ETB-selective agonist, BQ3020 at the highest concentration tested (10 microM) inhibited binding by only 50%. The non-selective RO462005 competed for the binding of [125I]-PD151242: KD = 1.31 +/- 1.38 microM, Bmax = 33.0 +/- 9.7 fmol mg-1 protein. Endothelin-2 and sarafotoxin S6B inhibited [125I]-PD151242 binding to renal tissue whereas ET-3 and sarafotoxin S6C were less effective. Non-endothelin and non-sarafotoxin peptides did not compete. 3. No degradation of [125I]-PD151242 was detected following incubation of the ligand with renal tissue under the conditions of the binding assay.(ABSTRACT TRUNCATED AT 250 WORDS)
机译:1.线性四肽放射性配体[125I] -PD151242用于表征人肾脏中的ETA受体,ETA受体是富含ETB的组织。用[125I] -PD151242进行的饱和结合测定揭示了一群高亲和力内皮素受体:KD = 0.75 +/- 0.07 nM和Bmax = 48.4 +/- 1.6 fmol mg-1蛋白(n = 3个人+/- semean )。坡度接近于统一,并且一个地点适合于两个地点模型。 2.ETA-受体选择性配体以亚纳摩尔亲和力竞争[125I] -PD151242结合:BQ123 KD = 0.43 +/- 0.10nM,Bmax = 46.6 +/- 7.9fmol mg-1蛋白; FR139317,KD = 0.37 +/- 0.06 nM,Bmax = 39.5 +/- 6.5 fmol mg-1蛋白(n = 3个个体+/- s.e.mean)。在每种情况下,均获得了单相抑制曲线,并且一个位点拟合优于两个位点模型。在最高测试浓度(10 microM)下,ETB选择性激动剂BQ3020仅抑制50%的结合。非选择性RO462005竞争[125I] -PD151242的结合:KD = 1.31 +/- 1.38 microM,Bmax = 33.0 +/- 9.7 fmol mg-1蛋白。内皮素2和sarafotoxin S6B抑制[125I] -PD151242与肾脏组织的结合,而ET-3和sarafotoxin S6C的效果较差。非内皮素和非sarafotoxin肽不竞争。 3.在结合测定条件下,将配体与肾脏组织一起孵育后,未检测到[125I] -PD151242的降解。(摘要截短为250字)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号